Trial reportScientific reports2026
Effects of prucalopride succinate on postoperative bowel motility and inflammation following minimally invasive gastrectomy.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The enhanced recovery after surgery (ERAS) protocol includes prokinetic agents to reduce postoperative ileus. This double-blind, randomized controlled trial enrolled patients scheduled for minimally invasive gastrectomy for gastric cancer. Patients were randomly assigned to receive either mosapride citrate (control) or prucalopride succinate (experimental) from postoperative days 1 to 4. Bowel motility was assessed by tracking radiopaque marker migration on serial abdominal radiographs, along with first-flatus time, food intake, and inflammatory markers. Baseline characteristics were comparable between groups. The primary endpoint, bowel transit rate on postoperative day 3, showed no significant difference between the control (58.3%) and experimental groups (67.5%, p = 0.223). However, on postoperative day 5, the experimental group showed significantly higher colonic transit (96.9% vs. 90.2%, p = 0.012) and a greater increase in oral intake over time. The neutrophil-to-lymphocyte ratio (NLR) was significantly lower in the experimental group on POD 3 (p = 0.035). Although prucalopride succinate did not accelerate recovery of bowel motility on POD 3, it demonstrated delayed physiological improvement by POD 5 and attenuation of early inflammatory markers, without significant differences in clinical outcomes. Further research is needed to obtain confirmatory evidence before routine incorporation into ERAS protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.